1.57
Marker Therapeutics Inc 주식(MRKR)의 최신 뉴스
Marker Therapeutics Partners with Cellipont for MT-601 Manufacturing - TipRanks
Marker Therapeutics Announces Collaboration with Cellipont Bioservices for cGMP Manufacturing of MT-601 T Cell Therapy - Nasdaq
Marker Therapeutics and Cellipont Bioservices Announce - GlobeNewswire
Marker's Breakthrough Lymphoma Treatment Hits 78% Response Rate, Secures Major Manufacturing Deal - Stock Titan
Compass Therapeutics, Inc. (NASDAQ:CMPX) Shares Sold by Millennium Management LLC - Defense World
Carisma Therapeutics, Inc. (NASDAQ:CARM) Stock Position Decreased by Millennium Management LLC - Defense World
Millennium Management LLC Takes Position in Marker Therapeutics, Inc. (NASDAQ:MRKR) - Defense World
Millennium Management LLC Invests $31,000 in Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) - Defense World
Millennium Management LLC Purchases Shares of 15,326 Hookipa Pharma Inc (NASDAQ:HOOK) - Defense World
Brookline Capital sets $4 target on Marker Therapeutics stock - MSN
Marker Therapeutics Reports Q1 2025 Financial Results - TipRanks
Northern Trust Corp Buys 21,703 Shares of Marker Therapeutics, Inc. (NASDAQ:MRKR) - Defense World
Capricor Therapeutics Inc (NASDAQ:CAPR) Shares Acquired by Nuveen Asset Management LLC - Defense World
Transcript : Marker Therapeutics, Inc.Special Call - marketscreener.com
Peptide Cancer Vaccine Market Detailed In New Research Report - openPR.com
Marker Therapeutics Reports Positive Impact of Lymphodepletion on MAR-T Cells - MSN
Lymphodepletion Enhances MAR T-Cell Expansion and Persistence in R/R Lymphoma - OncLive
MRKR: Promising Results from Phase 1 APOLLO Study on Lymphoma Treatment | MRKR Stock News - GuruFocus
Marker Therapeutics Reports that Lymphodepletion Improves - GlobeNewswire
Breakthrough: Marker's Cancer Treatment Achieves 78% Response Rate in Lymphoma Patients After CAR-T Failure - Stock Titan
MRKR FY2028 EPS Reduced by Brookline Capital Management - Defense World
Marker Therapeutics CEO Dr. Juan Vera to Join Expert Panel Discussing CD19 CAR-T Therapy at Upcoming Webcast - Nasdaq
Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies - The Manila Times
Leading Cancer Experts Reveal How MAR-T Technology Could Revolutionize CAR-T Cell Therapy Limitations - Stock Titan
Marker Therapeutics to Spotlight Multi-Antigen Recognizing - GlobeNewswire
Marker Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Hematopoietic stem cell transplantation Market: Investment - openPR.com
Peptide Cancer Vaccine Market Set to Witness Significant Growth - openPR.com
Marker Therapeutics (MRKR) Expected to Announce Earnings on Wednesday - Defense World
Peptide Cancer Vaccine Market Is Booming Worldwide | Marker - openPR.com
Matinas Biopharma (NYSE:MTNB) versus Marker Therapeutics (NASDAQ:MRKR) Head to Head Review - Defense World
Altesa BioSciences announces Katharine Knobil, M.D. as Chief Medical Officer - PR Newswire
Marker Therapeutics Advances T Cell Therapies in 2024 - TipRanks
LPL Financial LLC Acquires New Holdings in Marker Therapeutics, Inc. (NASDAQ:MRKR) - Defense World
Acute Myeloid Leukemia Drugs Market 2034: EMA, PDMA, FDA - openPR.com
MRKR stock touches 52-week low at $2.4 amid challenging year - MSN
Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results - ADVFN
Houston Biotechnology Company Brings Manufacturing Ops Home With New Facility - Bisnow
FibroBiologics opens cell therapy manufacturing space ahead of clinical trials - The Business Journals
Acute Myeloid Leukemia Treatment Market 2034: Clinical Trials, - openPR.com
Brookline Capital Management Comments on MRKR Q1 Earnings - Defense World
Marker Therapeutics (NASDAQ:MRKR) Receives Strong-Buy Rating from WBB Securities - The AM Reporter
Brookline Capital Management Estimates MRKR FY2026 Earnings - Defense World
Marker Therapeutics Full Year 2024 Earnings: Misses Expectations - Yahoo Finance
Breakthrough: New Alzheimer's Drug Cuts Key Brain Marker by 15%University Study Reveals - Stock Titan
Marker Therapeutics to Present at Canaccord Genuity’s Horizons in Oncology Conference - GlobeNewswire
MRKR stock touches 52-week low at $1.12 amid market challenges - Investing.com
Marker Therapeutics to Present at Canaccord Genuity's Horizons in Oncology Conference - The Manila Times
Revolutionary MAR-T Cell Therapy: Marker CEO Reveals Latest Advances in Solid Tumor Treatment - Stock Titan
Marker Therapeutics Advances MT-601 with Promising Results and Strategic Funding - TipRanks
자본화:
|
볼륨(24시간):